Ambisome is a medicine containing the active ingredient(s) liposomal amphotericin b. On this page you will find out more about Ambisome, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: liposomal amphotericin b
Information for medicine and pack size:
Ambisome 50 mg powder for injection, 1 vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS: Ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic Candida, Aspergillus and Cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to Amphotericin B (see Clinical Trials). Ambisome is indicated for the treatment of visceral leishmaniasis. Clinical studies of efficacy in visceral leishmaniasis are limited to Leishmania infantum. INDICATED AS AT 8 SEPTEMBER 2003 :AmBisome is indicated for: prophylaxis in liver transplant patients at risk of systemic Candida, Aspergillus and Cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to Amphotericin B (see Clinical Trials). AmBisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. AmBisome is indicated for the treatment of visceral leishmaniasis. Clinical studies of efficacy in visceral leishmaniasis are limited to Leishmania infantum.
Table of characteristics
|Visual appearance||A yellow lyophilised cake or powder.|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
10 x 50mg + 10 x 5 micrometre filters: Prescription Only Medicine, or Prescription Animal Remedy
single vial and a single 5um filter: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Light|
|Life time||4 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
AmBisome Powder for infusion - myDr.com.au
AmBisome Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Prevention of fungal infections in patients with cancer with amphotericin B | Cochrane
Read more on Cochrane (Australasian Centre) website